Virax Biolabs and Transcode Therapeutics Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV
RedChip Companies said it will air interviews with Virax Biolabs Group Ltd. (Nasdaq:VRAX) and Transcode Therapeutics Inc. (Nasdaq:RNAZ) on Bloomberg TV Aug 8 and CNBC Aug 9. Virax CEO James Foster discussed its fiscal 2026 annual report, Nasdaq bid compliance, and progress on ViraxImmune and ImmuneSelect, including a Fosun Diagnostics supply deal. Transcode CEO Philippe Calais discussed Phase 2a progress for TTX-MC138 and prior Phase 1a results.
How this was made
The 30-second read
Why it matters
The text provides specific operational and clinical milestones (Nasdaq compliance and Fosun supply agreement for VRAX; Phase 2a advancement for RNAZ) but lacks quantified financial impact, trial enrollment details, or regulatory outcomes.
Market read
This is primarily a scheduled media/interview promotion with embedded updates that could drive short-lived retail/sentiment flows, especially around RNAZ’s Phase 2a milestone.
What to watch
Traders should verify whether the Fosun supply agreement and the Phase 2a initiation were already disclosed in prior press releases or filings, since the article itself does not establish first-publication timing.
Background
RedChip Companies will air CEO interviews with Virax Biolabs (VRAX) and TransCode Therapeutics (RNAZ) on Bloomberg TV and CNBC, with discussion of business and clinical progress.
Ticker impact
Virax CEO interview highlights regained Nasdaq minimum bid compliance and progress on ViraxImmune and ImmuneSelect, including a new Fosun Diagnostics supply agreement.
Likely modest, headline-driven interest around the broadcast window; follow-through depends on whether investors treat the Fosun supply agreement as incremental revenue visibility.
The article is a promotional investor-relations update. It cites specific operational items (Nasdaq compliance, Fosun supply agreement, ImmuneSelect commercialization plan) but does not include quantified guidance, trial results, or regulatory decisions.
TransCode CEO interview says lead candidate TTX-MC138 is advancing into Phase 2a for ctDNA-positive colorectal cancer after Phase 1a safety/tolerability results.
Potential for a short-term positive reaction, especially if the market views Phase 2a initiation as de-risking versus earlier-stage development.
The article provides concrete clinical-stage progression and references Phase 1a endpoints (safety, tolerability, disease stabilization, no dose-limiting toxicities). However, it is still framed as an interview/PR and lacks trial size, endpoints, or timing details.
Market effects
Biotech small-cap investor-relations push may temporarily lift attention toward immune profiling and immuno-oncology names, but it does not signal sector-wide regulatory or funding changes.
No direct regional macro or policy linkage beyond US media distribution.
Fosun Diagnostics supply agreement reference links to Southeast Asia commercialization, but the article provides no deal size or revenue impact.
Counterpoint
Because this is a sponsored interview announcement, the market may discount it unless the underlying clinical/commercial details are already known or soon to be followed by filings with quantified terms.
Key entities
- companyVirax Biolabs Group Ltd.
Immune response detection and T cell immune profiling company; programs include ViraxImmune and ImmuneSelect.
- companyTransCode Therapeutics Inc.
Immuno-oncology and targeted cancer therapy company; lead candidate TTX-MC138 moving into Phase 2a.
- partnerFosun Diagnostics
Named as the counterparty in a supply agreement covering six Southeast Asian markets (as described in the interview summary).
- drug_candidateTTX-MC138
Lead therapeutic candidate discussed for Phase 2a in ctDNA-positive colorectal cancer.
